Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HME1 Etoposide
0.01
Topo II
Chemotherapy
 1.0051 0.00017
HME1 Etoposide
0.031667
Topo II
Chemotherapy
 0.9640 -0.00226
HME1 Etoposide
0.1
Topo II
Chemotherapy
 0.6098 0.03371
HME1 Etoposide
0.31623
Topo II
Chemotherapy
 0.1001 0.14130
HME1 Etoposide
1.0
Topo II
Chemotherapy
 -0.0664 0.24510
HME1 Etoposide
3.1623
Topo II
Chemotherapy
 -0.2086 0.48348
HME1 Etoposide
10.0
Topo II
Chemotherapy
 -0.3838 0.67631
HME1 Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 1.0615 0.01088
HME1 Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 1.0432 0.01694
HME1 Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 1.0641 0.02196
HME1 Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 0.9840 0.04553
HME1 Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.5914 0.04435
HME1 Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.3295 0.05581
HME1 Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 0.1804 0.06856
HME1 Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 -0.0053 0.08814
HME1 Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 -0.0749 0.10208
HME1 Trametinib
0.0001
MEK
MAPK/nRTK
 1.0990 0.00162
HME1 Trametinib
0.00031623
MEK
MAPK/nRTK
 1.0646 -0.00253
HME1 Trametinib
0.001
MEK
MAPK/nRTK
 0.9846 -0.00339
HME1 Trametinib
0.0031623
MEK
MAPK/nRTK
 0.7632 0.00378
HME1 Trametinib
0.01
MEK
MAPK/nRTK
 0.3263 0.03247
HME1 Trametinib
0.031623
MEK
MAPK/nRTK
 0.2597 0.03528
HME1 Trametinib
0.1
MEK
MAPK/nRTK
 0.2470 0.05553
HME1 Trametinib
0.31623
MEK
MAPK/nRTK
 0.2329 0.05550
HME1 Trametinib
1.0
MEK
MAPK/nRTK
 0.2032 0.05305